Exhibit 99.1 ALPHA TAU MEDICAL LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page | --- | --- | |----------------------------------------------------------------------------------|------------| | | | | Interim Consolidated Balance Sheets | 2 – 3 | | | | | Interim Consolidated Statements of Operations | 4 | | Interim Consolidated Statements of Changes in Shareholders' Equity | 5 | | | | | Interim Consolidated Statements of Cash Flows | 6 | | | | ...

The pooled analysis included data from 4 international clinical trials spanning an array of hard-to-treat indications including skin, head & neck, and oral cavity. Initial response data demonstrated an overall response rate of almost 100% in treated lesions and a complete response rate of 89%. With follow-up as long as 51 months (median follow-up of 14-months), no moderate or severe long-term toxicities were noted, and 2-year local recurrence-free survival was estimated at 77%. JERUSALEM, June 25, 2024 (GLO ...

decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it. Alpha Tau CEO Uzi Sofer stated, "We are encouraged by the perspective offered by this long-term data and its publication in a renowned journal such as Cancers. The publication of this comprehensive pooled ...

JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview and update at the Jefferies Global Healthcare Conference on June 5th, 2024. Event: Jefferies Global Healthcare Conference Date: June 5th, 2024 Time: 1:30-1:55 PM EST Location: New York, NY Mr. Levy will also be available for 1x1 investor meeti ...

- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow - - First patient with liver metastases treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada - - Patient recruitment for ReSTART U.S. multi-center pivotal trial and for pancreatic cancer feasibility and safety studies in Canada and Israel currently ongoing - - Cash, cash equivalents, deposits & restricted deposits ...

- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow - - First patient with liver metastases treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada - - Patient recruitment for ReSTART U.S. multi-center pivotal trial and for pancreatic cancer feasibility and safety studies in Canada and Israel currently ongoing - - Cash, cash equivalents, deposits & restricted deposits ...

JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with liver cancer metastases has been treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada. The trial seeks to recruit up to 10 patients who are eligible for a two-staged hepatectomy to resect liver metastases of ...

- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone - Effect seen across both Panc02 and KPC tumor models - JERUSALEM, May 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the presentation of new preclinical data at the 2024 congress of th ...

- Positive interim safety and feasibility data from pancreatic cancer study in Montreal, with initial signs of potential dose response findings - - ReSTART U.S. multi-center pivotal trial currently underway - - Submitted PMDA application for recurrent Head and Neck cancer in Japan - - Entered into long-term lease for a second facility in the U.S. in Hudson, NH - - Cash, deposits and restricted deposits balance of $84.9 million, with anticipated runway for at least two years - JERUSALEM, March 07, 2024 (GLOB ...

Exhibit 99.1 Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update - Positive interim safety and feasibility data from pancreatic cancer study in Montreal, with initial signs of potential dose response findings - - ReSTART U.S. multi-center pivotal trial currently underway - - Submitted PMDA application for recurrent Head and Neck cancer in Japan - - Entered into long-term lease for a second facility in the U.S. in Hudson, NH - - Cash, deposits and restricted deposits ba ...